PL2828259T3 - Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3 - Google Patents
Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3Info
- Publication number
- PL2828259T3 PL2828259T3 PL13763998T PL13763998T PL2828259T3 PL 2828259 T3 PL2828259 T3 PL 2828259T3 PL 13763998 T PL13763998 T PL 13763998T PL 13763998 T PL13763998 T PL 13763998T PL 2828259 T3 PL2828259 T3 PL 2828259T3
- Authority
- PL
- Poland
- Prior art keywords
- flt3 inhibitors
- substituted pyridopyrimidine
- pyridopyrimidine compounds
- compounds
- substituted
- Prior art date
Links
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000008518 pyridopyrimidines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/032575 WO2013142382A1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
| EP13763998.5A EP2828259B1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2828259T3 true PL2828259T3 (pl) | 2019-02-28 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13763998T PL2828259T3 (pl) | 2012-03-22 | 2013-03-15 | Podstawione związki pirydopirymidynowe oraz ich zastosowanie jako inhibitory flt3 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (enExample) |
| EP (1) | EP2828259B1 (enExample) |
| JP (1) | JP6101341B2 (enExample) |
| KR (1) | KR102011770B1 (enExample) |
| CN (1) | CN104428298B (enExample) |
| AU (1) | AU2013235344B2 (enExample) |
| BR (1) | BR112014023460B1 (enExample) |
| CA (1) | CA2868156C (enExample) |
| CL (1) | CL2014002505A1 (enExample) |
| EA (1) | EA031267B1 (enExample) |
| ES (1) | ES2694223T3 (enExample) |
| IL (1) | IL234802B (enExample) |
| IN (1) | IN2014MN02082A (enExample) |
| MX (1) | MX360912B (enExample) |
| MY (1) | MY184858A (enExample) |
| NZ (1) | NZ700283A (enExample) |
| PL (1) | PL2828259T3 (enExample) |
| SG (1) | SG11201405942RA (enExample) |
| TR (1) | TR201816480T4 (enExample) |
| WO (1) | WO2013142382A1 (enExample) |
| ZA (1) | ZA201407588B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102228034B1 (ko) * | 2013-10-21 | 2021-03-16 | 제노스코 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
| CN105272930B (zh) * | 2014-07-17 | 2018-07-13 | 广东东阳光药业有限公司 | 取代脲衍生物及其在药物中的应用 |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| US11608340B2 (en) | 2014-11-17 | 2023-03-21 | Rhode Island Hospital | Nanomaterial compositions, synthesis, and assembly |
| MX2020013805A (es) | 2018-06-27 | 2021-03-09 | Oscotec Inc | Derivados de piridopirimidinona para uso como inhibidores de axl. |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) * | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357634A1 (en) * | 2000-01-27 | 2004-07-26 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| BR0113590A (pt) * | 2000-08-31 | 2003-07-22 | Hoffmann La Roche | 7-oxo-piridopirimidinas |
| EP1315726A1 (en) * | 2000-08-31 | 2003-06-04 | F. Hoffmann-La Roche Ag | 7- oxo pyridopyrimidines as inhibitors of cellular proliferation |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| EP2330909B1 (en) * | 2008-08-12 | 2013-09-18 | GlaxoSmithKline LLC | Chemical compounds |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| JP2013502429A (ja) * | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | ビアリール化合物及びその使用方法 |
| CA2779105C (en) * | 2009-10-29 | 2016-08-16 | Hong Woo Kim | Kinase inhibitors |
-
2013
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active Active
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en not_active Ceased
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
-
2014
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015510942A (ja) | 2015-04-13 |
| CA2868156A1 (en) | 2013-09-26 |
| IN2014MN02082A (enExample) | 2015-08-21 |
| BR112014023460B1 (pt) | 2020-09-01 |
| TR201816480T4 (tr) | 2018-11-21 |
| MY184858A (en) | 2021-04-27 |
| US8877763B2 (en) | 2014-11-04 |
| CL2014002505A1 (es) | 2015-10-02 |
| IL234802B (en) | 2018-10-31 |
| MX360912B (es) | 2018-11-22 |
| AU2013235344A1 (en) | 2014-10-09 |
| CN104428298A (zh) | 2015-03-18 |
| HK1208453A1 (en) | 2016-03-04 |
| MX2014011354A (es) | 2014-12-05 |
| US20130274274A1 (en) | 2013-10-17 |
| EA031267B1 (ru) | 2018-12-28 |
| KR102011770B1 (ko) | 2019-08-19 |
| AU2013235344B2 (en) | 2017-03-16 |
| EA201491747A1 (ru) | 2015-10-30 |
| JP6101341B2 (ja) | 2017-03-22 |
| SG11201405942RA (en) | 2014-10-30 |
| CN104428298B (zh) | 2017-03-01 |
| WO2013142382A1 (en) | 2013-09-26 |
| NZ700283A (en) | 2016-08-26 |
| KR20140144709A (ko) | 2014-12-19 |
| ZA201407588B (en) | 2015-11-25 |
| CA2868156C (en) | 2020-07-28 |
| EP2828259A4 (en) | 2015-08-19 |
| EP2828259A1 (en) | 2015-01-28 |
| EP2828259B1 (en) | 2018-08-08 |
| ES2694223T3 (es) | 2018-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201407588B (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| HUE044300T2 (hu) | 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk | |
| AP4017A (en) | Substituted triazolopyridines and their use as ttk inhibitors | |
| ZA201503794B (en) | Imidazopyridine compounds | |
| IL237475A0 (en) | Pyrlotriazinone derivatives as pi3k inhibitors | |
| PL2800738T3 (pl) | Związki heterocykliczne i sposoby ich stosowania | |
| IL236535A0 (en) | Azaindole derivatives that act as pi3k inhibitors | |
| ZA201406082B (en) | Use of ccr3-inhibitors | |
| PL2912032T3 (pl) | Pochodne 4-karboksyamido-izoindolinonu jako selektywne inhibitory parp-1 | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| SI2912041T1 (sl) | Derivati tetrahidropirolotiazina kot inhibitorji beta sekretaze (bace) | |
| SG11201503977PA (en) | Azaindole derivatives as jak3 inhibitors | |
| IL239245A0 (en) | A new use of Eclidenium | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201213726D0 (en) | Novel compounds and their use |